VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 75 filers reported holding VAXCYTE INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,224,611 | -6.8% | 82,868 | -8.7% | 0.01% | 0.0% |
| Q2 2023 | $4,534,202 | +60.8% | 90,793 | +20.7% | 0.01% | +50.0% |
| Q1 2023 | $2,820,407 | -20.4% | 75,251 | +1.8% | 0.00% | -33.3% |
| Q4 2022 | $3,543,313 | +187.4% | 73,896 | +43.8% | 0.01% | +200.0% |
| Q3 2022 | $1,233,000 | +10.6% | 51,377 | +0.3% | 0.00% | 0.0% |
| Q2 2022 | $1,115,000 | +27.1% | 51,237 | +41.1% | 0.00% | +100.0% |
| Q1 2022 | $877,000 | -6.6% | 36,314 | -8.0% | 0.00% | 0.0% |
| Q4 2021 | $939,000 | -3.2% | 39,465 | +3.2% | 0.00% | 0.0% |
| Q3 2021 | $970,000 | -21.3% | 38,238 | -30.2% | 0.00% | -50.0% |
| Q2 2021 | $1,233,000 | +42.9% | 54,790 | +25.4% | 0.00% | +100.0% |
| Q1 2021 | $863,000 | +17.9% | 43,698 | +58.6% | 0.00% | 0.0% |
| Q4 2020 | $732,000 | -46.2% | 27,559 | 0.0% | 0.00% | -50.0% |
| Q3 2020 | $1,361,000 | – | 27,559 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $82,124,000 | 28.36% |
| Medicxi Ventures Management (Jersey) Ltd | 1,887,478 | $37,277,000 | 21.71% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,405,421 | $27,757,000 | 8.90% |
| FRAZIER MANAGEMENT LLC | 2,309,554 | $45,614,000 | 3.66% |
| RA Capital Management | 3,865,808 | $76,350,000 | 1.15% |
| TPG Group Holdings (SBS) Advisors, Inc. | 4,558,475 | $90,030,000 | 1.05% |
| Soleus Capital Management, L.P. | 293,650 | $5,800,000 | 1.04% |
| Opaleye Management Inc. | 357,800 | $7,067,000 | 1.04% |
| SABBY MANAGEMENT, LLC | 178,992 | $3,535,000 | 0.69% |
| Penn Mutual Asset Management | 22,227 | $439,000 | 0.50% |